Enozertinib vs Sevabertinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR/HER2 · full Non-Small Cell Lung Cancer pipeline

Enozertinib

Developed by ORIC Pharmaceuticals under a licence from Voronoi, Inc

Phase 1 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06816992 (registry estimate)

No aligned efficacy figure on record for this race.

Sevabertinib · Hyrnuo

Marketed by Bayer

Approved in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT06221475 · Phase 1 · completed

This was an unblinded, single-arm pharmacokinetic characterization study with no comparator group, so it provides no controlled evidence of clinical effect.

Next expected readout: October 2027 · NCT06452277 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEnozertinibSevabertinib
PFS, median—Not reported—Trial running · NCT06452277
OS, median—Not reported—Trial running · NCT06452277
ORR—Not reported—Trial running · NCT06452277
Duration of response, median—Not reported—Trial running · NCT06452277

PFS, median

Enozertinib
—Not reported
Sevabertinib
—Trial running · NCT06452277

OS, median

Enozertinib
—Not reported
Sevabertinib
—Trial running · NCT06452277

ORR

Enozertinib
—Not reported
Sevabertinib
—Trial running · NCT06452277

Duration of response, median

Enozertinib
—Not reported
Sevabertinib
—Trial running · NCT06452277
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Enozertinib: no structured comparison results are available for Non-Small Cell Lung Cancer.

Sevabertinib: no structured comparison results are available for Non-Small Cell Lung Cancer.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Enozertinib's landscape · Sevabertinib's landscape